Clarient, a provider of comprehensive anatomic pathology and molecular testing services, will acquire Applied Genomics in an all-stock merger worth up to $17.6 million.
Ambit and Astellas Sign $350M Development Deal
The deal will include Ambit’s AC220, a kinase inhibitor currently in Phase II trials to treat a form of blood cancer called acute relapsed/refractory myeloid leukemia (AML).
Potential Hepatitis C Breakthrough for Santaris
In preliminary testing done on chimpanzees chronically infected with the hepatitis C virus, SPC3649 dramatically reduced virus levels with no toxic side effects.
Clavis and Clovis Sign Licensing Deal for Cancer Drug
Start-up biotech Clovis Oncology has signed a $380 million deal to license an experimental pancreatic cancer drug from Norwegian company Clavis Pharma.
Micromet Signs $477M Deal with Sanofi-Aventis
Micromet has licensed one of its cancer-fighting antibody candidates to Sanofi-Aventis in a $477 million deal.
BioDelivery Sciences (NASDAQ: BDSI): Restarting the Catalyst Cycle
BDSI focuses on the niche market of pain management and supportive cancer care.
FDA Approves Centocor’s Psoriasis Treatment
After a long delay, Centocor Ortho Biotech’s psoriasis drug Stelara has been approved by the U.S. Food and Drug Administration.
NeoPharm Tipped As Stock to Watch
NeoPharm, a biopharmaceutical company developing drugs for cancer treatment, has been tipped as a worthwhile stock on financial website Seeking Alpha.
